Healthcare resource utilization and cost among patients treated for early-stage triple-negative breast cancer.

Abstract

Background: This retrospective, observational study examined real-world healthcare resource utilization (HCRU) and costs in 308 patients diagnosed with early-stage (II-IIIB) triple-negative breast cancer between 1 March 2008 and 31 March 2016. Methods: HCRU and costs were evaluated for two time periods: from neoadjuvant treatment start date to surgery (Time 1) and after surgery to recurrence or death (Time 2). Results: The sample included 236 patients who received neoadjuvant treatment without subsequent adjuvant treatment (Neo) and 72 patients who received neoadjuvant treatment followed by adjuvant treatment (Neo + adj). Mean monthly HCRU events and mean monthly costs per patient were higher in Time 1 compared with Time 2 for both groups. Conclusion: These results demonstrate the economic burden of early-stage triple-negative breast cancer especially during neoadjuvant treatment phase.

• Authors: Amin Haiderali, Whitney C Rhodes, Santosh Gautam, Min Huang, Jan Sieluk, Karen E Skinner, Lee S Schwartzberg
• Journal: Future oncology (London, England) (Future Oncol) Vol. 17 Issue 29 Pg. 3833-3841 (Oct 2021) ISSN: 1744-8301 [Electronic] England
• PMID: 34254533 (Publication Type: Journal Article, Observational Study)

Topics

• Adult
• Female
• Health Care Costs (statistics & numerical data)
• Humans
• Middle Aged
• Neoadjuvant Therapy
• Neoplasm Staging
• Patient Acceptance of Health Care (statistics & numerical data)
• Retrospective Studies
• Triple Negative Breast Neoplasms (pathology, therapy)